In September 2001 the FDA warned Merck, makers of the painkiller Vioxx, for engaging in a promotional campaign that minimized "potentially serious cardiovascular findings." The previous year, Merck spent $161 million on Vioxx advertising (more than Pepsi or Budweiser spent on advertising that year). Earlier this year, a securities class action complaint was filed on behalf of several Merck investors alleging the company engaged in a marketing campaign that included false and misleading statements concerning the safety profile of Vioxx and that company insiders sold personally held shares of Merck for over $175 million in proceeds. Today, Merck withdrew Vioxx from the market.
posted by Otis
on Sep 30, 2004 -
19 comments